BioElectronics Corporation
BioElectronics Corporation Fundamental Analysis
BioElectronics Corporation (BIEL) shows weak financial fundamentals with a PE ratio of -10.62, profit margin of -1.88%, and ROE of 5.49%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -132.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BIEL's fundamental strength across five key dimensions:
Efficiency Score
WeakBIEL struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBIEL trades at attractive valuation levels.
Growth Score
WeakBIEL faces weak or negative growth trends.
Financial Health Score
ModerateBIEL shows balanced financial health with some risks.
Profitability Score
WeakBIEL struggles to sustain strong margins.
Key Financial Metrics
Is BIEL Expensive or Cheap?
P/E Ratio
BIEL trades at -10.62 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BIEL's PEG of -0.11 indicates potential undervaluation.
Price to Book
The market values BioElectronics Corporation at -0.57 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 21.12 times EBITDA. This signals the market has high growth expectations.
How Well Does BIEL Make Money?
Net Profit Margin
For every $100 in sales, BioElectronics Corporation keeps $-1.88 as profit after all expenses.
Operating Margin
Core operations generate -79.17 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.49 in profit for every $100 of shareholder equity.
ROA
BioElectronics Corporation generates $-21.48 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioElectronics Corporation generates limited operating cash flow of $-120.11K, signaling weaker underlying cash strength.
Free Cash Flow
BioElectronics Corporation generates weak or negative free cash flow of $-120.11K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
BIEL converts -2.27% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-10.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
-0.57
vs 25 benchmark
P/S Ratio
Price to sales ratio
14.58
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.89
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.01
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
-21.48
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How BIEL Stacks Against Its Sector Peers
| Metric | BIEL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -10.62 | 29.45 | Better (Cheaper) |
| ROE | 5.49% | 779.00% | Weak |
| Net Margin | -187.62% | -24930.00% (disorted) | Weak |
| Debt/Equity | -0.89 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 0.01 | 4.65 | Weak Liquidity |
| ROA | -2148.02% | -19333.00% (disorted) | Weak |
BIEL outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioElectronics Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation